[{"from": "human", "value": "Provide a description of this molecule. [C][C][C][N][Branch1][Branch1][C][C][Ring1][=Branch1][C][Branch2][Ring1][N][C][C][N][Branch1][Branch1][C][C][Ring1][=Branch1][C][C][C][C][=Branch1][C][=O][C][=C][C][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][F][C][=Branch1][C][=O][N]"}, {"from": "gpt", "value": "The molecule is a typical antipsychotic of the butyrophenone family used in the treatment of schizophrenia. It was developed by Janssen Pharmaceutica in 1961 and started its first round of clinical trials in 1963.  In an effort to improve [haloperidol]'s pharmacological effects, Janssen discovered that pipamperone, an agent whose pharmacological profile was distinct from haloperidol and all other known antipsychotic drugs at this time, had significant anti-tryptamine activity. Some studies suggest pipamperone was the first atypical antipsychotic. Interestingly, when [risperidone] was created, Janssen suggested it was a more potent version of pipamperone. Synthesized in the year 1984, risperidone\u2019s pharmacological properties were similar to pipamperone\u2019s in that both block more serotonin more potently than dopamine."}]